Get the Stockscreener App
90.75
0.60%
0.54
After Hours:
90.25
-0.50
-0.55%
Boston Scientific Corp stock is traded at $90.75, with a volume of 3.66M.
It is up +0.60% in the last 24 hours and up +7.10% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
See More
Previous Close:
$90.21
Open:
$90.4
24h Volume:
3.66M
Relative Volume:
0.65
Market Cap:
$133.32B
Revenue:
$15.91B
Net Income/Loss:
$1.79B
P/E Ratio:
110.67
EPS:
0.82
Net Cash Flow:
$1.89B
1W Performance:
+0.64%
1M Performance:
+7.10%
6M Performance:
+19.99%
1Y Performance:
+62.96%
1-Day Range:
$90.05
$91.03
1-Week Range:
$87.95
$91.93
52-Week Range:
$53.93
$91.93
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific stock holds rating after Axonics acquisition - Investing.com
Boston Scientific expanding again in Maple Grove - The Business Journals
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet - Nasdaq
Boston Scientific to acquire Intera Oncology, terms not disclosed - Yahoo Finance
Boston Scientific EVP Arthur Butcher sells $1.25 million in stock By Investing.com - Investing.com South Africa
Boston Scientific EVP Arthur Butcher sells $1.25 million in stock - Investing.com
Boston Scientific's SWOT analysis: medtech leader's stock poised for growth - Investing.com
Boston Scientific expands infusion offerings with Intera Oncology acquisition - Medical Device Network
Boston Scientific to acquire Intera Oncology - Investing.com
Boston Scientific Announces Agreement to Acquire Intera Oncology® Inc. - Quantisnow
Boston Scientific to buy Intera Oncology, maker of liver cancer treatment - Yahoo Finance
Artificial Organs Market is Expected to Develop at a Stellar 7.68% CAGR through 2031 | SkyQuest Technology - GlobeNewswire Inc.
Electrophysiology Market Top PlayersAbbott, Medtronic, - openPR
Analysts Set Boston Scientific Co. (NYSE:BSX) Target Price at $93.39 - MarketBeat
Boston Scientific Co. (NYSE:BSX) Director Edward J. Ludwig Sells 4,877 Shares - MarketBeat
Boston Sci. Completes $3.7B Axonics Buy - Orange County Business Journal
Boston Scientific director sells $446,901 in stock - Investing.com India
Boston Scientific director sells $446,901 in stock By Investing.com - Investing.com South Africa
Boston Scientific (BSX) Announces 2025 Compensation Plans - GuruFocus.com
Insider Sell: Edward Ludwig Sells Shares of Boston Scientific Co - GuruFocus.com
Boston Scientific sets 2025 bonus, performance plans - Investing.com
Boston Scientific Launches 2025 Incentive Programs - TipRanks
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Why Is Boston Scientific (BSX) Up 7.5% Since Last Earnings Report? - Yahoo Finance
If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Boston Scientific (FRA:BSX) 3-Year Revenue Growth Rate : 11.60% (As of Sep. 2024) - GuruFocus.com
Boston Scientific (FRA:BSX) Purchase Of Investment : €0 Mil (TTM As of Sep. 2024) - GuruFocus.com
Boston Scientific (FRA:BSX) 5-Year EBITDA Growth Rate : 7.40% (As of Sep. 2024) - GuruFocus.com
Boston Scientific (FRA:BSX) Total Inventories : €2,480 Mil (As of Sep. 2024) - GuruFocus.com
Boston Scientific (FRA:BSX) Net-Net Working Capital : €-7.10 (As of Sep. 2024) - GuruFocus.com
Boston Scientific (FRA:BSX) EBIT : €2,281 Mil (TTM As of Sep. 2024) - GuruFocus.com
Boston Scientific Corporation (BSX)’s Breakthroughs: A Hidden Gem in Billionaire Ken Griffin’s Portfolio - Insider Monkey
Boston Scientific Co. (NYSE:BSX) Stake Boosted by PNC Financial Services Group Inc. - MarketBeat
Boston Scientific Stock Set to Gain From Completion of Axonics Deal - Yahoo Finance
Boston Scientific Corp (BSX) Shares Up 3.98% on Nov 19 - GuruFocus.com
Boston Sci study shows Watchman Flx better OPTION than DOAC - BioWorld Online
Boston Scientific Completes $3.7B Acquisition of Axonics - Orange County Business Journal
Boston Scientific reiterates Buy stock rating on Option study - Investing.com
Boston Scientific stock soars to all-time high of $89.33 - Investing.com
Boston Scientific stock soars to all-time high of $89.33 By Investing.com - Investing.com Canada
Here's Why We Think Boston Scientific (NYSE:BSX) Might Deserve Your Attention Today - Yahoo Finance
Boston Scientific’s Watchman could be new option for patients post ablation: study - Yahoo Finance
Boston Scientific reports outcomes from trial of LAAC device - Medical Device Network
Boston Scientific acquires Axonics - Medical Buyer
Boston Scientific to Acquire Cortex - Today's Medical Developments
Boston Scientific's WATCHMAN FLX Shows Superior Bleeding Risk Reduction in 3-Year Study | BSX Stock News - StockTitan
Boston Scientific (BSX) Completes Acquisition of Axonics - GuruFocus.com
Boston Scientific put volume heavy and directionally bearish - TipRanks
Boston Scientific Closes $3.7B Deal for Axonics - MPO-mag
Boston Scientific Closes Acquisition of Axonics, Inc. - Quantisnow
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):